Everest Medicines Limited (Stock Code: 1952) has released a notice of an extraordinary general meeting (EGM) to be held on Tuesday, 24 February 2026 at 10:00 a.m. via an online platform. Shareholders are invited to vote on several ordinary resolutions outlined in the notice dated 4 February 2026.

According to the announcement, the agenda includes: (1) approving, confirming, and ratifying the Commercialization Service Agreement and related transactions; (2) approving and confirming the grant of 530,303 awards to a key management member under the Pre-IPO ESOP; (3) approving and adopting the 2026 Share Scheme with a Scheme Mandate Limit of 10% of the total issued and outstanding shares (excluding any treasury shares) at the time of shareholder approval; and (4) conditionally approving and adopting a 0.5% Service Provider Sublimit within the 2026 Share Scheme if the preceding resolution is passed.

Shareholders who wish to exercise their voting rights must submit a form of proxy to the Company’s Hong Kong Share Registrar, Computershare Hong Kong Investor Services Limited, at least 48 hours before the meeting. The notice specifies that those appointed as proxies must have a valid email address to receive the login details for the virtual platform. The Company has stated that attendance and voting through the online platform are irrevocable once the voting session concludes.